Shield Therapeutics (STX) Competitors

Shield Therapeutics logo
GBX 3.05 +0.05 (+1.67%)
As of 11:32 AM Eastern

STX vs. BVXP, AGY, VLG, ORPH, and EAH

Should you buy Shield Therapeutics stock or one of its competitors? Shield Therapeutics's main competitors and comparable companies include Bioventix (BVXP), Allergy Therapeutics (AGY), Venture Life Group (VLG), Open Orphan (ORPH), and ECO Animal Health Group (EAH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Shield Therapeutics compare to Bioventix?

Bioventix (LON:BVXP) and Shield Therapeutics (LON:STX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

In the previous week, Bioventix's average media sentiment score of 0.00 equaled Shield Therapeutics'average media sentiment score.

Company Overall Sentiment
Bioventix Neutral
Shield Therapeutics Neutral

Bioventix has a beta of 0.541, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Shield Therapeutics has a beta of 1.768, suggesting that its stock price is 77% more volatile than the broader market.

20.6% of Bioventix shares are owned by institutional investors. Comparatively, 6.7% of Shield Therapeutics shares are owned by institutional investors. 6.2% of Bioventix shares are owned by insiders. Comparatively, 3.0% of Shield Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Bioventix has higher earnings, but lower revenue than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bioventix£12.97M8.05£8.12M£143.6213.91
Shield Therapeutics£58.63M0.56-£36.28M-£1.00N/A

Bioventix has a net margin of 58.70% compared to Shield Therapeutics' net margin of -17.76%. Bioventix's return on equity of 67.81% beat Shield Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Bioventix58.70% 67.81% 54.07%
Shield Therapeutics -17.76%64.57%-47.85%

Summary

Bioventix beats Shield Therapeutics on 9 of the 11 factors compared between the two stocks.

How does Shield Therapeutics compare to Allergy Therapeutics?

Allergy Therapeutics (LON:AGY) and Shield Therapeutics (LON:STX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

In the previous week, Allergy Therapeutics had 5 more articles in the media than Shield Therapeutics. MarketBeat recorded 5 mentions for Allergy Therapeutics and 0 mentions for Shield Therapeutics. Allergy Therapeutics' average media sentiment score of 0.02 beat Shield Therapeutics' score of 0.00 indicating that Allergy Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Allergy Therapeutics Neutral
Shield Therapeutics Neutral

Allergy Therapeutics has a beta of 0.835, meaning that its stock price is 17% less volatile than the broader market. Comparatively, Shield Therapeutics has a beta of 1.768, meaning that its stock price is 77% more volatile than the broader market.

Shield Therapeutics has higher revenue and earnings than Allergy Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than Allergy Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allergy Therapeutics£57.29M1.44-£52.59M-£0.97N/A
Shield Therapeutics£58.63M0.56-£36.28M-£1.00N/A

Shield Therapeutics has a net margin of -17.76% compared to Allergy Therapeutics' net margin of -86.04%. Allergy Therapeutics' return on equity of 1,684.19% beat Shield Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Allergy Therapeutics-86.04% 1,684.19% -34.76%
Shield Therapeutics -17.76%64.57%-47.85%

0.0% of Allergy Therapeutics shares are held by institutional investors. Comparatively, 6.7% of Shield Therapeutics shares are held by institutional investors. 3.6% of Allergy Therapeutics shares are held by insiders. Comparatively, 3.0% of Shield Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Allergy Therapeutics beats Shield Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Shield Therapeutics compare to Venture Life Group?

Venture Life Group (LON:VLG) and Shield Therapeutics (LON:STX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

In the previous week, Venture Life Group's average media sentiment score of 0.00 equaled Shield Therapeutics'average media sentiment score.

Company Overall Sentiment
Venture Life Group Neutral
Shield Therapeutics Neutral

Venture Life Group has a beta of 0.234, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Shield Therapeutics has a beta of 1.768, suggesting that its stock price is 77% more volatile than the broader market.

Venture Life Group has a net margin of 17.42% compared to Shield Therapeutics' net margin of -17.76%. Shield Therapeutics' return on equity of 64.57% beat Venture Life Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Venture Life Group17.42% 7.82% 1.56%
Shield Therapeutics -17.76%64.57%-47.85%

20.7% of Venture Life Group shares are held by institutional investors. Comparatively, 6.7% of Shield Therapeutics shares are held by institutional investors. 7.7% of Venture Life Group shares are held by company insiders. Comparatively, 3.0% of Shield Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Venture Life Group has higher earnings, but lower revenue than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than Venture Life Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Venture Life Group£35.17M2.34£747.21K£4.3715.84
Shield Therapeutics£58.63M0.56-£36.28M-£1.00N/A

Summary

Venture Life Group beats Shield Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Shield Therapeutics compare to Open Orphan?

Open Orphan (LON:ORPH) and Shield Therapeutics (LON:STX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Open Orphan has a net margin of 0.00% compared to Shield Therapeutics' net margin of -17.76%. Shield Therapeutics' return on equity of 64.57% beat Open Orphan's return on equity.

Company Net Margins Return on Equity Return on Assets
Open OrphanN/A N/A N/A
Shield Therapeutics -17.76%64.57%-47.85%

Open Orphan has higher earnings, but lower revenue than Shield Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Open Orphan£34.71M0.00N/AN/AN/A
Shield Therapeutics£58.63M0.56-£36.28M-£1.00N/A

6.7% of Shield Therapeutics shares are owned by institutional investors. 3.0% of Shield Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Open Orphan's average media sentiment score of 0.00 equaled Shield Therapeutics'average media sentiment score.

Company Overall Sentiment
Open Orphan Neutral
Shield Therapeutics Neutral

Summary

Shield Therapeutics beats Open Orphan on 5 of the 7 factors compared between the two stocks.

How does Shield Therapeutics compare to ECO Animal Health Group?

Shield Therapeutics (LON:STX) and ECO Animal Health Group (LON:EAH) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

ECO Animal Health Group has higher revenue and earnings than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than ECO Animal Health Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shield Therapeutics£58.63M0.56-£36.28M-£1.00N/A
ECO Animal Health Group£87.53M0.61£1.05M£3.1525.40

6.7% of Shield Therapeutics shares are held by institutional investors. Comparatively, 40.9% of ECO Animal Health Group shares are held by institutional investors. 3.0% of Shield Therapeutics shares are held by insiders. Comparatively, 11.3% of ECO Animal Health Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Shield Therapeutics has a beta of 1.768, meaning that its stock price is 77% more volatile than the broader market. Comparatively, ECO Animal Health Group has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

ECO Animal Health Group has a consensus target price of GBX 160, indicating a potential upside of 99.95%. Given ECO Animal Health Group's stronger consensus rating and higher possible upside, analysts plainly believe ECO Animal Health Group is more favorable than Shield Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Shield Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
ECO Animal Health Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

ECO Animal Health Group has a net margin of 2.50% compared to Shield Therapeutics' net margin of -17.76%. Shield Therapeutics' return on equity of 64.57% beat ECO Animal Health Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Shield Therapeutics-17.76% 64.57% -47.85%
ECO Animal Health Group 2.50%2.55%2.14%

In the previous week, ECO Animal Health Group had 1 more articles in the media than Shield Therapeutics. MarketBeat recorded 1 mentions for ECO Animal Health Group and 0 mentions for Shield Therapeutics. Shield Therapeutics' average media sentiment score of 0.00 equaled ECO Animal Health Group'saverage media sentiment score.

Company Overall Sentiment
Shield Therapeutics Neutral
ECO Animal Health Group Neutral

Summary

ECO Animal Health Group beats Shield Therapeutics on 13 of the 15 factors compared between the two stocks.

Get Shield Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for STX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

STX vs. The Competition

MetricShield TherapeuticsPharmaceuticals IndustryHealthcare SectorLON Exchange
Market Cap£32.76M£13.61B£7.74B£2.79B
Dividend YieldN/A2.58%2.46%5.11%
P/E Ratio-3.0529.4134.1723.17
Price / Sales0.567.028.485.10
Price / Cash6.3615.7421.9320.23
Price / Book55.735.114.372.48
Net Income-£36.28M£2.88B£3.52B£5.88B
7 Day Performance-8.05%-4.11%-5.47%-1.22%
1 Month Performance-42.18%-5.09%-4.58%-2.86%
1 Year Performance-55.60%-7.45%-1.79%6.43%

Shield Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STX
Shield Therapeutics
N/AGBX 3.05
+1.7%
N/A-55.4%£32.76M£58.63MN/A40,000
BVXP
Bioventix
N/AGBX 1,970
flat
N/A-12.3%£102.93M£12.97M13.7212
AGY
Allergy Therapeutics
N/AGBX 1.49
flat
N/A-82.9%£94.36M£57.29MN/A612
VLG
Venture Life Group
N/AGBX 69
flat
N/A+15.2%£82.02M£35.17M15.79165
ORPH
Open Orphan
N/AN/AN/AN/A£67.09M£34.71MN/A179

Related Companies and Tools


This page (LON:STX) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners